Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎, New York, NY 10065
(646) 856-9261
[email protected]

Anne Assmus, Ph.D.

Head of Business Development

Anne heads business development at RGENIX, where she focuses on strategic partnerships for the target discovery platform, preclinical and clinical stage programs.
Prior to joining Rgenix, Anne was VP of Business Development at Affimed, Inc. where she supported the partnering of the NK cell platform and clinical programs.
Anne brings over a decade of business development experience to Rgenix across technologies ranging from antibodies, cell therapies and cancer vaccines, to small molecules and diagnostics and across stages of programs from target discovery to phase 3. She holds a Ph.D. in economics from the University of Passau in Germany, an M.Sc. in Molecular Biology from Heidelberg University in Germany, and a B.Sc. in International Business from Copenhagen Business School in Denmark.